Medroxyprogesterone Acetate
"Medroxyprogesterone Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.
| Descriptor ID |
D017258
|
| MeSH Number(s) |
D04.210.500.745.745.654.829.395.700.500
|
| Concept/Terms |
Medroxyprogesterone Acetate- Medroxyprogesterone Acetate
- Depo-Medroxyprogesterone Acetate
- Depo Medroxyprogesterone Acetate
- 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate
- 6 alpha Methyl 17alpha hydroxyprogesterone Acetate
- (6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione
- Medroxyprogesterone 17-Acetate
- Medroxyprogesterone 17 Acetate
|
Below are MeSH descriptors whose meaning is more general than "Medroxyprogesterone Acetate".
Below are MeSH descriptors whose meaning is more specific than "Medroxyprogesterone Acetate".
This graph shows the total number of publications written about "Medroxyprogesterone Acetate" by people in this website by year, and whether "Medroxyprogesterone Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 2 | 3 |
| 2008 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Medroxyprogesterone Acetate" by people in Profiles.
-
Ectopic pregnancy prevention: Further evidence of benefits of prescription contraceptives. Contraception. 2022 01; 105:19-25.
-
Depot Medroxyprogesterone Acetate, Oral Contraceptive, Intrauterine Device Use, and Fracture Risk. Obstet Gynecol. 2019 09; 134(3):581-589.
-
Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial. Obstet Gynecol. 2017 01; 129(1):121-129.
-
Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. J Natl Cancer Inst. 2016 Mar; 108(3).
-
Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013 Aug 12; 173(15):1429-36.
-
Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use. Contraception. 2012 Jan; 85(1):36-41.
-
One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives. Obstet Gynecol. 2011 Feb; 117(2 Pt 1):363-71.
-
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010 Oct 20; 304(15):1684-92.
-
Hormone therapy and physical function change among older women in the Women's Health Initiative: a randomized controlled trial. Menopause. 2010 Mar; 17(2):295-302.
-
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008 Mar 05; 299(9):1036-45.